---
layout: minimal-medicine
title: Tegafur + Gimeracil + Oteracil
---

# Tegafur + Gimeracil + Oteracil
### Generic Name
Tegafur + Gimeracil + Oteracil (S-1)

### Usage
Tegafur, Gimeracil, and Oteracil, often referred to as S-1, is a combination chemotherapy drug used to treat several types of advanced cancer.  Its primary use is in the treatment of advanced gastric (stomach) cancer, often in combination with cisplatin.  It's also used as postoperative adjuvant therapy for locally advanced gastric cancer (stages II, IIIA, or IIIB, according to the Japanese Classification of Gastric Carcinoma).  Furthermore, S-1 is indicated for the treatment of advanced or recurrent head and neck cancer and advanced or metastatic pancreatic adenocarcinomas.

### Dosage
Dosage is complex and depends on several factors, including the specific cancer being treated and the patient's body surface area (BSA).  It is crucial to consult a healthcare professional for precise dosage instructions.  The dosage is generally calculated based on the Tegafur component and is administered orally.  There are different formulations with varying ratios of Tegafur, Gimeracil, and Oteracil.  Commonly used regimens involve daily doses for a set period (e.g., 21 days) followed by a break before the next cycle. Dosage adjustments are frequently necessary based on individual patient response and tolerance, and factors like renal or hepatic function.  Pediatric use is not recommended.  Detailed dosage regimens and adjustments for specific scenarios (e.g., renal or hepatic impairment, obesity) are available in the full prescribing information.

### Side Effects
S-1, like most chemotherapy drugs, can cause side effects.  The severity and frequency vary among individuals.

**Common Side Effects:**

*   Fatigue
*   Nausea
*   Vomiting
*   Diarrhea
*   Anorexia (loss of appetite)
*   Constipation
*   Mouth sores (stomatitis)
*   Skin rash
*   Changes in skin pigmentation
*   Anemia
*   Leukopenia (low white blood cell count)
*   Neutropenia (low neutrophil count)
*   Thrombocytopenia (low platelet count)
*   Peripheral neuropathy (numbness or tingling in the extremities)


**Less Common but Serious Side Effects:**

*   Severe bone marrow suppression
*   Severe liver damage (hepatotoxicity), potentially leading to liver failure
*   Severe kidney damage (nephrotoxicity)
*   Cardiovascular problems (e.g., heart failure, angina)
*   Severe allergic reactions
*   GI bleeding
*   Bowel obstruction


If you experience any of these side effects, especially if they are severe or persistent, it's crucial to contact your healthcare provider immediately.

### How it Works
Tegafur is a prodrug, meaning it's converted into an active form (5-fluorouracil or 5-FU) in the body. 5-FU interferes with DNA and RNA synthesis, ultimately inhibiting the growth and replication of cancer cells. Gimeracil inhibits the breakdown of 5-FU, increasing its concentration in the body and enhancing its anticancer effect. Oteracil reduces 5-FU activity in healthy intestinal cells, minimizing side effects in the digestive tract.  The combined action of these three components makes S-1 a more targeted and effective chemotherapy option compared to 5-FU alone.


### Precautions
Several precautions must be considered when using S-1:

*   **Allergic Reactions:**  Individuals with known allergies to any of the components should avoid this medication.
*   **Drug Interactions:**  S-1 can interact with other drugs; informing your healthcare provider of all medications you're taking is crucial to avoid potential adverse effects.  Particular caution is warranted with other fluoropyrimidines, certain anticoagulants, and some enzyme inhibitors.
*   **Pre-existing Conditions:**  Patients with pre-existing liver or kidney disease, bone marrow suppression, or cardiovascular problems require careful monitoring during treatment.
*   **Pregnancy and Breastfeeding:** S-1 is contraindicated during pregnancy and breastfeeding due to potential harm to the fetus or infant. Effective contraception should be used.
*   **DPD Deficiency:** Patients with dihydropyrimidine dehydrogenase (DPD) deficiency are at significantly increased risk of severe toxicity from 5-FU and should not receive S-1. Testing for DPD deficiency is recommended prior to treatment initiation.


### FAQs
*   **How should I store S-1?** Follow the storage instructions provided by your pharmacist.  Generally, it should be kept at room temperature, away from moisture and direct sunlight.
*   **Can I drink alcohol while taking S-1?**  Alcohol consumption should be discussed with your doctor, as it could interact with the medication or exacerbate side effects.
*   **What should I do if I miss a dose?** Don't attempt to make up for missed doses. Consult your healthcare professional for guidance.
*   **Is S-1 safe for everyone?** No, S-1 is not suitable for everyone. Several factors, including pre-existing conditions and other medications, need consideration before treatment.
*   **How long will I be on S-1?** The duration of treatment varies depending on your individual response to therapy and the type of cancer being treated.  Your doctor will determine the appropriate treatment length.

**Disclaimer:** This information is for general knowledge and should not be considered medical advice.  Always consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.  The prescribing information should be consulted for complete details.
